Related Experiment Video
Updated: May 19, 2026
08:19
Solid Lipid Nanoparticles (SLNs) for Intracellular Targeting Applications
Published on: November 17, 2015
Long-term stability, biocompatibility and oral delivery potential of risperidone-loaded solid lipid nanoparticles
1Laboratory of Pharmaceutical Technology/Centre of Research in Pharmaceutical Sciences, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal. ana.silva@ff.up.pt
International Journal of Pharmaceutics
|August 8, 2012
Summary
Solid lipid nanoparticles (SLN) effectively deliver risperidone (RISP) orally. These stable SLN formulations show good biocompatibility and controlled drug release, highlighting their potential for poorly water-soluble drugs.
Area of Science:
- Pharmaceutical Nanotechnology
- Drug Delivery Systems
Background:
- Risperidone (RISP) is a poorly water-soluble antipsychotic drug with challenges in oral administration.
- Solid lipid nanoparticles (SLN) offer a promising approach to enhance the oral bioavailability of such drugs.
Purpose of the Study:
- To design and evaluate a Compritol®-based solid lipid nanoparticle (SLN) formulation for improved oral delivery of risperidone (RISP).
- To assess the stability, biocompatibility, and in vitro release characteristics of the developed SLN formulation.
Main Methods:
- Lipid screening for risperidone solubility, SLN preparation using Compritol®, long-term stability testing (particle size, PI, ZP, EE), TEM imaging.
- Oxidative potential measurement, Caco-2 cell biocompatibility assay (MTT), in vitro drug release and transport studies.
Main Results:
- Compritol®-based SLN formulations demonstrated excellent long-term stability over two years.
- High encapsulation efficiency (EE) and consistent particle morphology were observed.
- Fickian diffusion governed drug release; SLN formulations were biocompatible and showed dose-dependent drug transport across Caco-2 cells.
Conclusions:
- The developed risperidone-loaded SLN formulation is stable, biocompatible, and suitable for oral drug delivery.
- SLN technology presents a viable strategy for enhancing the oral delivery of poorly water-soluble drugs like risperidone.
Related Concept Videos
01:05Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
01:20Modified-Release Drug Delivery Systems: Influencing Factors
Modified-release drug delivery systems are designed to optimize the therapeutic effect of drugs by minimizing side effects, reducing the dosage required, and controlling drug release to align with pharmacokinetic and pharmacodynamic needs. The system depends on two key factors: the drug's release from the formulation and its movement through the body to the target site. Unlike conventional dosage forms, where absorption is the limiting step, the rate of drug release is the key determinant in...
01:26Oral Drug Delivery Systems: Continuous-Release Systems
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
01:30Modified-Release Drug Delivery Systems: Bioavailability
Modified-release (MR) dosage forms are designed to extend drug release over time, thereby maintaining stable plasma concentrations and reducing dosing frequency. However, their bioavailability is typically below 100% due to incomplete drug release and presystemic metabolism, and limitations in drug permeability across the gastrointestinal epithelium, all of which can restrict the fraction of the drug reaching systemic circulation. Consequently, studying the in vivo bioavailability of MR...
01:27Bioavailability Enhancement: Drug Permeability Enhancement
After oral administration, poor permeability often limits the rate at which drugs are absorbed through the intestinal epithelium. Enhancing drug permeability is crucial for effective therapy, and several strategies have been developed to overcome this challenge.One effective strategy involves the use of lipid-based formulations. These formulations enhance dissolution and solubility, targeting physiological mechanisms to increase drug absorption. This includes stimulating bile salt secretion,...
01:19Modified-Release Drug Delivery Systems: Overview
Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...